Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial

• FDA cleared Adicet Bio’s IND for ADI-212 in metastatic castration-resistant prostate cancer.
• Phase 1 enrollment is expected to start in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608271600BIZWIRE_USPR_____20260827_BW653039) on August 27, 2026, and is solely responsible for the information contained therein.